Besides, no significant differences appeared in the exhaustion markers of T cells (PD1, TIM3, and LAG3) and PD-L1 of tumor cells in the tumor site after CLDN18.2-mBBZ or FAP-mBBZ CAR-T treatment (Additional file 1: Fig.S6b, d). This evidence concerns the gene HAVCR2 and neoplasm.